Form 4: Coeptis Therapeutics Director Philippe Deschamps Reports Stock Option Grant
SEC Form 4 Filing
Director Philippe Deschamps reports receiving a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.
Summary
- On March 10, 2025, Philippe Deschamps, a director of Coeptis Therapeutics Holdings, Inc., filed a Form 4.
- The form reports the grant of 5,700 non-qualified stock options on March 4, 2025.
- The exercise price of the options is $10.56, equal to the company's stock price on the grant date.
- The options vest in four equal installments over one year, starting on March 31, 2025, and expiring ten years from the grant date.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction (stock option grant) |
| 03/04/2025 | Grant date of 5,700 non-qualified stock options |
| 03/31/2025 | First vesting date (25%) of the stock options |
| 06/30/2025 | Second vesting date (25%) of the stock options |
| 09/30/2025 | Third vesting date (25%) of the stock options |
| 12/31/2025 | Final vesting date (25%) of the stock options |
| 03/10/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.